Bibliographie (2530)
![[Preprint] Heparin for Moderately Ill Patients with Covid-19 – “In moderately ill ward patients with Covid-19 and elevated D-dimer level, therapeutic heparin did not significantly reduce the primary outcome but decreased the odds of death at 28 days”.](/media/k2/items/cache/e3823fe2e02931eee83f491ba1ee32af_L.jpg)
[Preprint] Heparin for Moderately Ill Patients with Covid-19 – “In moderately ill ward patients with Covid-19 and elevated D-dimer level, therapeutic heparin did not significantly reduce the primary outcome but decreased the odds of death at 28 days”.
lundi, 12 juillet 2021 05:49 Écrit par Zouhair SouissiHeparin for Moderately Ill Patients with Covid-19 – medRxiv Related: RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk. AND [Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin […]
The post [Preprint] Heparin for Moderately Ill Patients with Covid-19 – “In moderately ill ward patients with Covid-19 and elevated D-dimer level, therapeutic heparin did not significantly reduce the primary outcome but decreased the odds of death at 28 days”. appeared first on Links Medicus.
RCT: Another study shows Azithromycin does improve outcomes in patients with Covid-19.
lundi, 12 juillet 2021 05:49 Écrit par Zouhair SouissiAzithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial – The Lancet Respiratory Medicine Commentaries: Trial shows that the antibiotic azithromycin does not prevent mild COVID cases progressing to hospitalization, death – European Society of Clinical Microbiology and Infectious Diseases AND Azithromycin: can its benefit be ruled out in mild […]
The post RCT: Another study shows Azithromycin does improve outcomes in patients with Covid-19. appeared first on Links Medicus.
Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report.
lundi, 12 juillet 2021 03:46 Écrit par Zouhair SouissiUnderstanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report – Annals of the American Thoracic Society
The post Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. appeared first on Links Medicus.
2021 ACR Guideline for the Management of ANCA–Associated Vasculitis.
vendredi, 09 juillet 2021 13:21 Écrit par Zouhair Souissi2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis – Arthritis & Rheumatology
The post 2021 ACR Guideline for the Management of ANCA–Associated Vasculitis. appeared first on Links Medicus.
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
vendredi, 09 juillet 2021 13:21 Écrit par Zouhair SouissiReduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization – Nature Commentaries: Study highlights need for full Covid vaccination to protect against Delta variant – STAT AND How does the Delta variant dodge the immune system? Scientists find clues. – The New York Times Commentary on Twitter (thread – click for more) Just published […]
The post Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. appeared first on Links Medicus.
Will COVID become a disease of the young? – “A growing share of infections among unvaccinated youths in countries with high vaccination rates is putting the spotlight on the role of young people in the pandemic”.
vendredi, 09 juillet 2021 13:21 Écrit par Zouhair SouissiWill COVID become a disease of the young? – Nature
The post Will COVID become a disease of the young? – “A growing share of infections among unvaccinated youths in countries with high vaccination rates is putting the spotlight on the role of young people in the pandemic”. appeared first on Links Medicus.
RCT: CoronaVac showed efficacy of 83.5% for preventing symptomatic SARS-CoV-2 infection.
vendredi, 09 juillet 2021 13:20 Écrit par Zouhair SouissiEfficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey – The Lancet Invited commentary: CoronaVac: more data for regulators and policy makers Commentary on Twitter NEW—Interim analysis from phase 3 trial suggests efficacy of 2 doses of #CoronaVac is 83.5% against […]
The post RCT: CoronaVac showed efficacy of 83.5% for preventing symptomatic SARS-CoV-2 infection. appeared first on Links Medicus.
After the pandemic: perspectives on the future trajectory of COVID-19.
vendredi, 09 juillet 2021 13:20 Écrit par Zouhair SouissiAfter the pandemic: perspectives on the future trajectory of COVID-19 – Nature
The post After the pandemic: perspectives on the future trajectory of COVID-19. appeared first on Links Medicus.
CDC: Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients – “Continued use of mRNA COVID-19 vaccines in all recommended age groups will prevent morbidity and mortality from COVID-19 that far exceed the number of cases of myoc
vendredi, 09 juillet 2021 13:20 Écrit par Zouhair SouissiUse of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021 – Centers for Disease Control and Prevention Commentary on Twitter In a new @CDCMMWR, the Advisory Committee on Immunization Practices recommends everyone 12 & older get a #COVID19 vaccine. […]
The post CDC: Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients – “Continued use of mRNA COVID-19 vaccines in all recommended age groups will prevent morbidity and mortality from COVID-19 that far exceed the number of cases of myocarditis expected”. appeared first on Links Medicus.
Review: Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS.
jeudi, 08 juillet 2021 12:33 Écrit par Zouhair SouissiNon-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS – Intensive Care Medicine Commentary on Twitter Physiology-to-bedside overview about non-invasive ventilatory support in AHRF & #ARDS➡️spontaneous breathing: benefits/harms➡️how to make spontaneous effort non‑injurious?➡️optimizing HFNO & NIV➡️monitoring to detect failure & be protective➡️evidencehttps://t.co/KPW2u8akhA pic.twitter.com/yKVxrYaFmZ — Intens Care […]
The post Review: Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS. appeared first on Links Medicus.
